We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
IBA Announces Expansion of Collaboration with MorphoSys AbD Serotec
News

IBA Announces Expansion of Collaboration with MorphoSys AbD Serotec

IBA Announces Expansion of Collaboration with MorphoSys AbD Serotec
News

IBA Announces Expansion of Collaboration with MorphoSys AbD Serotec

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "IBA Announces Expansion of Collaboration with MorphoSys AbD Serotec"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

IBA GmbH (Goettingen) has announced the signing of a second license agreement with MorphoSys AG regarding recombinant antibody purification using IBA’s proprietary Strep-tag® technology.

The original research license agreement dating back to the year 2000 has now been complemented with a second license agreement rendering the commercial use of IBA’s Strep-tag patent rights for custom service purification of antibodies by AbD Serotec, a business unit of MorphoSys AG.

The license granted by IBA is worldwide and non-exclusive. Recent IBA developments in the Strep-tag field had proven to be advantageous compared to other tag-systems for automated batch purification of recombinant antibodies.

"We are very pleased to announce an expansion of one of our earliest and most productive Strep-tag out-licensing opportunities to date," commented Alois Schneiderbauer, Chief Business Officer of IBA.

"Expanding our existing collaborations is a cornerstone of our strategy and we have been very successful in this regard."

"The extended agreement provides a higher number of antibodies carrying a Strep-tag to the market, allowing e.g. for their convenient detection and immobilisation."

Advertisement